RIGEL PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$150.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-02
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$150.00K.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $2.11M, a 83.44% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $10.39M, a 66.09% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $19.15M.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $24.88M, a 44.23% decline from fiscal 2015.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $44.61M, a 29.11% decline from fiscal 2014.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $62.93M, a 13.07% decline from fiscal 2013.
- RIGEL PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $72.40M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|
| 2017-03-31 | -$150.00K 10-Q · filed 2017-05-02 | $1.96M derived: sum of 2 quarters · filed 2017-05-02 | $12.35M derived: sum of 3 quarters · filed 2017-05-02 | $31.50M derived: sum of 4 quarters · filed 2017-05-02 | ||
| 2016-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $12.50M derived: sum of 2 quarters · filed 2017-03-07 | $31.65M derived: sum of 3 quarters · filed 2017-03-07 | $24.88M 10-K · filed 2017-03-07 | ||
| 2016-09-30 | $10.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $29.54M derived: sum of 2 quarters · filed 2016-11-01 | $22.77M 10-Q · filed 2016-11-01 | $35.52M derived: sum of 4 quarters · filed 2017-05-02 | ||
| 2016-06-30 | $19.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $12.38M 10-Q · filed 2016-08-02 | $25.13M derived: sum of 3 quarters · filed 2017-05-02 | $55.77M derived: sum of 4 quarters · filed 2017-05-02 | ||
| 2016-03-31 | -$6.77M 10-Q · filed 2017-05-02 | $5.98M derived: sum of 2 quarters · filed 2017-05-02 | $36.63M derived: sum of 3 quarters · filed 2017-05-02 | $28.33M derived: sum of 4 quarters · filed 2017-05-02 | ||
| 2015-12-31 | $12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $43.40M derived: sum of 2 quarters · filed 2017-03-07 | $35.10M derived: sum of 3 quarters · filed 2017-03-07 | $44.61M 10-K · filed 2017-03-07 | ||
| 2015-09-30 | $30.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $22.35M derived: sum of 2 quarters · filed 2016-11-01 | $31.86M 10-Q · filed 2016-11-01 | $48.78M derived: sum of 4 quarters · filed 2017-03-07 | ||
| 2015-06-30 | -$8.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $1.22M 10-Q · filed 2016-08-02 | $18.13M derived: sum of 3 quarters · filed 2017-03-07 | $25.43M derived: sum of 4 quarters · filed 2017-03-07 | ||
| 2015-03-31 | $9.51M 10-Q · filed 2016-05-03 | $26.42M derived: sum of 2 quarters · filed 2017-03-07 | $33.73M derived: sum of 3 quarters · filed 2017-03-07 | $61.98M derived: sum of 4 quarters · filed 2017-03-07 | ||
| 2014-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | $24.22M derived: sum of 2 quarters · filed 2017-03-07 | $52.47M derived: sum of 3 quarters · filed 2017-03-07 | $62.93M 10-K · filed 2017-03-07 | ||
| 2014-09-30 | $7.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $35.56M derived: sum of 2 quarters · filed 2015-11-03 | $46.02M 10-Q · filed 2015-11-03 | $45.97M 10-Q · filed 2014-11-04 | $69.52M derived: sum of 4 quarters · filed 2016-03-08 | |
| 2014-06-30 | $28.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $38.72M 10-Q · filed 2015-08-04 | $62.21M derived: sum of 3 quarters · filed 2016-03-08 | $77.12M derived: sum of 4 quarters · filed 2016-03-08 | ||
| 2014-03-31 | $10.46M 10-Q · filed 2015-05-07 | $33.96M derived: sum of 2 quarters · filed 2016-03-08 | $48.86M derived: sum of 3 quarters · filed 2016-03-08 | $57.07M derived: sum of 4 quarters · filed 2016-03-08 | ||
| 2013-12-31 | $23.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $38.40M derived: sum of 2 quarters · filed 2016-03-08 | $46.61M derived: sum of 3 quarters · filed 2016-03-08 | $72.40M 10-K · filed 2016-03-08 | $72.38M 10-K · filed 2014-03-04 | |
| 2013-09-30 | $14.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $23.11M derived: sum of 2 quarters · filed 2014-11-04 | $48.90M 10-Q · filed 2014-11-04 | -$59.37M derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | $8.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $33.99M 10-Q · filed 2014-08-05 | -$74.28M derived: sum of 3 quarters · filed 2015-03-03 | -$55.20M derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-03-31 | $25.79M 10-Q · filed 2014-05-07 | -$82.48M derived: sum of 2 quarters · filed 2015-03-03 | -$63.41M derived: sum of 3 quarters · filed 2015-03-03 | -$39.43M derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2012-12-31 | -$108.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$89.19M derived: sum of 2 quarters · filed 2015-03-03 | -$65.22M derived: sum of 3 quarters · filed 2015-03-03 | -$39.03M 10-K · filed 2015-03-03 | -$39.05M 10-K · filed 2013-03-05 | |
| 2012-09-30 | $19.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $43.05M derived: sum of 2 quarters · filed 2013-11-05 | $69.24M 10-Q · filed 2013-11-05 | $87.07M derived: sum of 4 quarters · filed 2014-03-04 | ||
| 2012-06-30 | $23.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $50.16M 10-Q · filed 2013-08-06 | $67.99M derived: sum of 3 quarters · filed 2014-03-04 | $56.50M derived: sum of 4 quarters · filed 2014-03-04 | ||
| 2012-03-31 | $26.18M 10-Q · filed 2013-05-07 | $44.02M derived: sum of 2 quarters · filed 2014-03-04 | $32.52M derived: sum of 3 quarters · filed 2014-03-04 | -$74.45M derived: sum of 4 quarters · filed 2014-03-04 | ||
| 2011-12-31 | $17.84M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $6.34M derived: sum of 2 quarters · filed 2014-03-04 | -$100.64M derived: sum of 3 quarters · filed 2014-03-04 | -$62.85M 10-K · filed 2014-03-04 | ||
| 2011-09-30 | -$11.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$118.47M derived: sum of 2 quarters · filed 2012-11-06 | -$80.68M 10-Q · filed 2012-11-06 | -$104.64M derived: sum of 4 quarters · filed 2013-03-05 | ||
| 2011-06-30 | -$106.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$69.19M 10-Q · filed 2012-08-07 | -$93.14M derived: sum of 3 quarters · filed 2013-03-05 | |||
| 2011-03-31 | $37.79M 10-Q · filed 2012-05-01 | $13.84M derived: sum of 2 quarters · filed 2013-03-05 | ||||
| 2010-12-31 | -$23.95M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-05 | -$53.40M 10-K · filed 2013-03-05 | ||||
| 2010-09-30 | -$29.45M 10-Q · filed 2011-11-01 | |||||
| 2009-12-31 | -$30.66M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |